Weight loss

FDA
#FDA #GLP-1 #Novo Nordisk #Obesity #Weight loss

FDA approves first oral GLP-1 for weight management

The US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.  The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy… Read More

#News #Regulatory #Trending News

#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Oral GLP-1 helps patients maintain weight loss after injectables

Lilly’s orforglipron has helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase III trial.  The ATTAIN-MAINTAIN trial evaluated orforglipron, a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks… Read More

#Editor's Choice #News

#GLP-1 #Mergers and acquisitions #Pfizer #Weight loss

Pfizer boosts weight loss pipeline with GLP-1 drug

Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of ShangAhai Fosun Pharmaceutical, for the development, manufacturing and commercialisation of YP05002.  YP05002 is a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase I development for chronic weight management.  “We look forward… Read More

#Business & Investment #News

Metsera logo
#Mergers and acquisitions #Metsera #Novo Nordisk #Obesity #Pfizer #Weight loss

Pfizer finally wins bidding war to acquire Metsera

Following a week-long bidding war with Novo Nordisk, Pfizer has acquired obesity drug specialists Metsera for $10 billion, thanks to an intervention by the US Federal Trade Commission (FTC).  Metsera's Board of Directors unanimously recommended that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the… Read More

#Business & Investment #News #Trending News

Monoclonal antibody
#Antibody #iBio #Obesity #Preclinical development #Weight loss

Twice-yearly antibody shows strong therapeutic potential for weight-loss

iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data.  The findings will be presented during an oral session at ObesityWeek 2025, taking place 4-7 November in Atlanta, USA. … Read More

#News #Trending News

Woman standing on scales
#Fundraising #Metabolic diseases #Obesity #Pila Pharma #Weight loss

Pila Pharma raises SEK 30 million to fund obesity studies

Biotech company Pila Pharma has recently completed a strongly oversubscribed share issue on Nasdaq First North in Stockholm.   The company says the raised capital of nearly SEK 30 million ($3 million) will finance the first steps of development of its tablet-based treatment for obesity.  Founded by former Novo Nordisk researcher… Read More

#Business & Investment #News

#Dementia #GLP-1 #Lupus #Menopause #Weight loss

This week in Drug Discovery (27 – 31 October)

News round-up for 27 – 31 October by Bruno Quinney, Content Team at DDW.  Women’s health is top of this week’s agenda, as Bayer paves the way for a new approach to treat hot flashes due to menopause. Elsewhere, an anti-obesity medication has health benefits beyond weight… Read More

#News

Patient injects Ozempic
#Diabetes #GLP-1 #Innovent #Phase III trial #Weight loss

Mazdutide shows superiority to semaglutide in a head-to-head trial

In the Phase III DREAMS-3 clinical trial of mazdutide, the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist showed superior efficacy to semaglutide for body weight reduction.  In Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide performed better than semaglutide on the primary endpoint,… Read More

#News #Trending News

Woman standing on scales
#Adverse event #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Mixed top-line results for Viking’s oral obesity drug

Viking Therapeutics has released positive top-line results from its Phase II clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.   VK2735 is being developed in both oral and subcutaneous formulations for… Read More

#News #Trending News

Weight loss concept
#GLP-1 #GPCRs #Nxera Pharma #Obesity #Weight loss

Nxera unveils obesity and chronic weight management pipeline

Biopharmaceutical company Nxera Pharma has launched a broad new pipeline strategically focused on advancing therapies for obesity and associated metabolic disorders.  Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline… Read More

#News

#Diabetes #GLP-1 #Mass spectrometry / NMR #Weight loss

How mass spectrometry is supporting GLP-1 breakthroughs in diabetes care

Kean Woodmansey, Senior Global Market Development Manager, Discovery (DMPK), SCIEX, examines how molecular precision is being enabled in GLP-1 therapies through the use of mass spectrometry. On Diabetes Alert Day in March, professionals across healthcare, research, and pharmaceutical development reflected on the pressing need for improved diabetes detection and treatment. Read More

#Exclusive Content #Trends & Analysis

#Denmark #Drug development #Funding #Obesity #Pila Pharma #Type 2 diabetes #Weight loss

Biotech raises capital for new oral obesity treatment

Biotech company Pila Pharma has raised 20 million Swedish kronor ($2.08 million) in an almost fully covered capital raise, which includes a stock option for future use. Pila Pharma was founded by Danish researcher Dorte Gram, a former researcher at Novo Nordisk and was the first researcher to screen and… Read More

#Business & Investment #News

Human gastrointestinal tract
#Assays #Drug discovery #Guide #In vivo #Obesity #Weight loss

Guide: Accelerate your weight loss drug discovery

A new Guide is now available from Eurofins Discovery entitled ‘Drug Discovery for Anti-Obesity‘. Explore obesity case studies profiling semaglutide, tirzepatide, and retatrutide using Eurofins Discovery’s weight-loss solutions. Advance your obesity program with on/off-target panels, translational assays, in vivo models, and MOA-reflective tools. Partner with expert scientists and program… Read More

#News

Drug Discovery for Anti-Obesity
#Assays #Drug discovery #In vivo #Obesity #Weight loss

Accelerate your weight loss drug discovery

Explore obesity case studies profiling semaglutide, tirzepatide, and retatrutide using Eurofins Discovery’s weight-loss solutions. Advance your obesity program with on/off-target panels, translational assays, in vivo models, and MOA-reflective tools. Partner with expert scientists and program managers for strategic guidance and scientific leadership on your integrated drug discovery programs targeting weight-loss… Read More

#Resources

Weight loss concept
#GLP-1 #Metabolic diseases #Obesity #Protagonist Therapeutics #Weight loss

Triple agonist designed to outperform GLP-1 drugs for obesity

Protagonist Therapeutics has announced a new, highly potent oral triple agonist peptide development candidate for obesity.   With once-daily dosing, PN-477o targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors.  The company has announced it will also develop a subcutaneous version, PN-477sc, as… Read More

#News

#Diabetes #Liver disease #Metabolic diseases #Obesity #Weight loss

New DDW Highlights podcast: 27 May 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this week focus on drug discovery for metabolic diseases, with a… Read More

#News